UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V.

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly making materially false and misleading statements regarding its business and operations during the specified class period from September 24, 2025, to October 31, 2025 [2][3] Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased uniQure ordinary shares during the class period [2] - Investors have until April 13, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2] Group 2: Allegations - The complaint alleges that uniQure's management made materially false statements and failed to disclose adverse facts about the company's business [3] - Specific allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline [3] - As a result, the statements made by the defendants regarding the company's business and prospects lacked a reasonable basis [3] Group 3: Next Steps for Investors - Investors who purchased uniQure shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4] - The law firm offers a no-cost consultation for affected investors [4]